Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.64 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386840 | 1.00 | PTPN1 (0.64) | PTPN1TLR2KMT2AMDM4TP53 | |
| SCHEMBL29872083 | 0.92 | PTPN1 (0.60) | PTPN1TLR2MDM4TP53GRB2 | |
| SCHEMBL30153671 | 0.92 | PTPN1 (0.56) | PTPN1MDM4TP53CASP3MDM2 | |
| SCHEMBL29700028 | 0.92 | PTPN1 (0.56) | PTPN1MDM4TP53CASP3MDM2 | |
| SCHEMBL29990051 | 0.92 | PTPN1 (0.56) | PTPN1MDM4TP53CASP3MDM2 | |
| SCHEMBL12658035 | 0.92 | PTPN1 (0.58) | PTPN1TLR2KMT2AMDM4TP53 | |
| SCHEMBL30163429 | 0.91 | PTPN1 (0.56) | PTPN1TLR2KMT2ACASP3GRB2 | |
| SCHEMBL29505149 | 0.90 | CASP3 (0.56) | PTPN1KMT2AMDM4TP53CASP3 | |
| SCHEMBL14719947 | 0.90 | KMT2A (0.57) | PTPN1TLR2KMT2AMDM4TP53 | |
| SCHEMBL14997839 | 0.89 | KMT2A (0.58) | PTPN1TLR2KMT2AMDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114933634-B | Synthesis method of acetyl hexadecapeptide | 陕西未来多肽生物科技有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-113501871-B | Method for preparing darunavagon by combining solid phase with liquid phase | 汉肽生物医药集团有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-114933634-A | Synthesis method of acetyl hexapeptide | 陕西未来多肽生物科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-118955683-A | Semex lattice Synthesis method of lupeptide | 泰州兴普泰生物制药有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | PEPTISTAR INC. (JP) | 2024-09-26 | — | — | US | disclosed |
| CN-114933634-B | Synthesis method of acetyl hexadecapeptide | 陕西未来多肽生物科技有限公司 | 2024-08-09 | — | — | CN | disclosed |
| EP-4365184-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | Peptistar Inc. (JP) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023277186-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | ペプチスター株式会社 | 2023-01-05 | — | — | WO | disclosed |
| CN-113501871-B | Method for preparing darunavagon by combining solid phase with liquid phase | 汉肽生物医药集团有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-113501871-B | Method for preparing darunavagon by combining solid phase with liquid phase | 汉肽生物医药集团有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-114933634-A | Synthesis method of acetyl hexapeptide | 陕西未来多肽生物科技有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-111349155-B | Glucagon analogue and preparation method and application thereof | 浙江和泽医药科技股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-113880936-B | Solid-phase synthesis method of abamectin | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | HDGF, VIP, NPPA | PTPN1 4090/4885TLR2 4291/4885KMT2A 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.